Skip to main content

Table 1 Summary of DSC3 expression and methylation state in primary breast tumors

From: Epigenetic silencing of DSC3 is a common event in human breast cancer

Cell/tumor Expressiona Methylationb %Mec Age (years) Histology
HMEC 100.0% - 15 N/A N/A
MCF10A 150.0% - 7 N/A N/A
120T 81.4% - 3 59 IDC
7732T 6.9% - 10 44 IDC
6385T 0.0% ++ 69 70 IDC
173T 0.1% + 30 55 IDC
8900T 77.2% - 2 56 IDC
4658T 52.4% - 8 83 IDC
7768T 2.3% - 7 40 IDC
2504T 67.8% - 16 53 IDC
9613T 8.0% - 9 42 IDC
6010T 0.3% + 21 55 IDC
2909T 26.3% - 1 38 IDC
2845T 0.0% ++ 49 77 IDC
d5974-1T 10.0% + 23 43 IDC
d5974-2T 10.0% ++ 48 43 IDC
7093T 10.0% + 30 63 IDC
9068T 0.0% - 8 73 IDC
4392T 0.0% + 33 47 IDC
5799T 0.0% + 22 53 IDC
6245T 0.0% - 1 30 IDC
2405T 30.0% + 20 58 IDC
2420T 0.0% - 8 54 IDC
5256T 3.9% - 1 60 IDC
1139T 6.4% - 11 40 IDC lymph node Met.
9663T 0.1% + 60 41 IDC lymph node Met.
9985T 5.8% - 0 61 ILC
7788T 1.3% + 23 76 ILC
6861T 20.2% + 29 71 ILC
5358T 73.9% ++ 58 42 ILC
6608T 5.6% - 8 74 ILC
7491T 30.0% - 2 64 ILC
6809T 0.0% ++ 49 57 ILC
4099T 0.6% + 37 43 Mucoid ductal CA
  1. aRNA expression levels determined by quantitative real-time PCR and relative to human mammary epithelial cells (HMECs). bCpG island methylation levels determined by bisulfite sequencing: ++, >40% methylation of total CpG sites analyzed; +, >20% methylation of total CpG sites; -, <20% methylation of total CpG sites analyzed. cPercent methylation was calculated based on the number of methylated CpG sites compared to the total number of sites analyzed. dTwo independent tumors isolated from the same breast. IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; N/A, not applicable, IDC lymph node Met, invasive ductal carcinoma that metastasized to the lymph node, Mucoiod Ductal CA, mucinous ductal carcinoma.